Treatment (as Prevention) Availability and Individuals’ Behavior: A Cost-Effectiveness Analysis of Cabotegravir Long-Acting Injectable PrEP
Our findings suggest that, even when considering potential shifts toward riskier behaviors, introducing long-acting PrEP remains cost-effective when compared with daily oral PrEP treatments.
Authors
- J. Felipe Montano-Campos (ORCID: https://orcid.org/0000-0003-0641-2500)
- Blythe J. S. Adamson (ORCID: https://orcid.org/0000-0003-4251-2912)
Institutions
- Seattle Pacific University (US)
- Pacific Northwest Diabetes Research Institute (US)
- Ministry of Economics (LV)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1007/s41669-025-00599-7
- Citations
- 2
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.79